Related Experiment Videos
Genetic and biological determinants of pulmonary embolism: Insights from Mendelian randomization studies
Rupak Desai1, Darsh Patel2, Abhishek Prasad3
1Outcomes Research, Independent Researcher, Atlanta, GA 30033, United States.
Abstract:
Pulmonary embolism (PE) is a common and potentially fatal thromboembolic disease contributing to a major global public health burden. Its pathogenesis involves multiple hemodynamic, inflammatory, metabolic, and genetic factors. The multifactorial nature of PE makes it difficult to infer the direct effects of risk factors using conventional statistical approaches because of potential confounding and reverse causality. Mendelian randomization (MR) uses genetic variants as instrumental variables to strengthen causal inference. This narrative review synthesizes the available MR literature concerning potential causative factors of PE, with particular emphasis on genetic and biological pathways. MR evidence suggests that matrix metalloproteinases (MMP)-19 may be associated with increased PE susceptibility, whereas MMP-12 may be associated with decreased susceptibility. Impaired kidney function showed a positive association with PE risk, and reduced HLA-DR+ NK cell traits were linked to PE pathogenesis. Among gut microbiota, Clostridium innocuum was associated with increased PE risk, whereas Butyricicoccus and Actinobacteria showed protective associations. No consistent causal associations were identified for type 2 diabetes, atrial fibrillation, or epigenetic age acceleration. Larger multiethnic studies integrating multi-omics data are needed to clarify mechanisms underlying PE pathogenesis.
Related Concept Videos
Pulmonary Embolism I: Introduction
Pulmonary Embolism I: Introduction
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Principles of Pharmacogenetics: Types of Genetic Variants
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Pharmacogenomics: Identification of New Drug Targets